BMS-986012 + cisplatin + etoposide

**BMS-986012 + cisplatin + etoposide** is a drug combination investigated for the treatment of extensive-stage small cell lung cancer (ES-SCLC). BMS-986012 is a nonfucosylated, fully human IgG1 monoclonal antibody that targets fucosyl-GM1, a monosialoganglioside highly expressed on SCLC cells but limited in healthy tissue. Its mechanism involves immune-mediated tumor cell killing, particularly antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and complement-dependent cytotoxicity (CDC). Cisplatin and etoposide are chemotherapeutic agents that induce cancer cell death via DNA damage and inhibition of topoisomerase II, respectively. The combination is studied as first-line treatment in ES-SCLC, with BMS-986012 used together with cisplatin and etoposide for four cycles, followed by BMS-986012 monotherapy until disease progression. The combination aims to enhance antitumor effects by complementing direct cytotoxic activity with immune modulation[1][2].